SCHEMBL26686993

SCHEMBL26686993

CCCOc1nc(C)c(C(=O)O)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
TSHR P16473 2/20 0.47
HPGD P15428 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.41
TARBP2 Q15633 1/20 0.41
KDM4E B2RXH2 5/20 0.41
RAB9A P51151 3/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 1/20 0.40
NPC1 O15118 2/20 0.39
POLB P06746 1/20 0.39
PIK3CD O00329 1/20 0.38
PIK3CA P42336 1/20 0.38
PIK3CB P42338 1/20 0.38
PKM P14618 1/20 0.37
HSP90AA1 P07900 1/20 0.37
RARB P10826 1/20 0.36
P2RX3 P56373 1/20 0.36
PDE5A O76074 1/20 0.35
PDE1A P54750 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9644950 0.86 ALDH1A1 (0.50) ALDH1A1TSHRHPGDSMN1; SMN2TARBP2
SCHEMBL18114028 0.85 ALDH1A1 (0.46) ALDH1A1TSHRHPGDSMN1; SMN2TARBP2
SCHEMBL8307559 0.77 ALDH1A1 (0.55) ALDH1A1TSHRHPGDSMN1; SMN2TARBP2
Hydrochloric Acid SCHEMBL9643731 0.75 ALDH1A1 (0.53) ALDH1A1TSHRHPGDSMN1; SMN2TARBP2
SCHEMBL26847416 0.74 ELANE (0.37) ALDH1A1SMN1; SMN2KDM4ERAB9ANPC1
SCHEMBL21939504 0.73 RARB (0.41) ALDH1A1TSHRHPGDKDM4ERAB9A
SCHEMBL12272041 0.72 NPC1 (0.44) SMN1; SMN2TARBP2KDM4ERAB9AGAA
SCHEMBL9957284 0.71 ALDH1A1 (0.39) ALDH1A1TSHRHPGDSMN1; SMN2KDM4E
SCHEMBL27812300 0.71 XDH (0.43) ALDH1A1TSHRHPGDSMN1; SMN2TARBP2
SCHEMBL20267640 0.71 MAPT (0.48) ALDH1A1TSHRHPGDSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4578451-A2 COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS Novartis AG (CH) 2025-07-02 EP disclosed
EP-4214210-B1 COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS NOVARTIS AG (CH) 2025-04-09 EP disclosed
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS NOVARTIS AG (CH) 2023-11-16 US disclosed
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS NOVARTIS AG (CH) 2023-11-16 US disclosed
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS NOVARTIS AG (CH) 2023-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS SPPL2A, SPPL2B, BACE1 ALDH1A1 3565/4885TSHR 4010/4885HPGD 2716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.